Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7EJI9
|
|||
| Drug Name |
UPB-101
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [1] | |
| Company |
Upstream Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymic stromal lymphoprotein receptor (CRLF2) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05448651) A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending-Dose Study to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of UPB-101 in Subjects With Asthma. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Upstream Biosciences | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.